Medical technology start-up Thrixen announced that it was able to raise $9.53m following the closing of an oversubscribed funding round co-led by new investors 22Health Ventures, an early-stage health technology venture firm, and Aldevron co-founder John Ballantyne.
“At the heart of this innovation is Thrixen’s proprietary assay technology, a protein engineering platform that replaces the use of antibodies, which has proven 99.5% sensitivity in clinical trials conducted to date,” the company said.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: